MethylGene Oncology Agent Shows Activity In NHL Clinical Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
MGCD0103 shows 15 percent response rate in subset of NHL patients, tumor shrinkage, firm reports at ASCO.
You may also be interested in...
MethylGene Backs Away From Stalled Phase II Cancer Drug
Reworking the MGCD0103 deal with Celgene frees resources for other work.
MethylGene Backs Away From Stalled Phase II Cancer Drug
Reworking the MGCD0103 deal with Celgene frees resources for other work.
FDA Makes Official MethylGene’s Partial Clinical Hold On ‘0103 Trials
With partner Celgene, the firm had already suspended enrollment in Phase I and Phase II trials due to cases of pericarditis.